Akanda Corp
NASDAQ:AKAN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/IC
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Valuation Scenarios
If EV/IC returns to its 3-Year Average (57.4), the stock would be worth $136.64 (179% upside from current price).
| Scenario | EV/IC Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 20.6 | $48.96 |
0%
|
| 3-Year Average | 57.4 | $136.64 |
+179%
|
| 5-Year Average | 86.7 | $206.45 |
+322%
|
| Industry Average | 0 | $0.01 |
-100%
|
| Country Average | 0 | $0.01 |
-100%
|
Forward EV/IC
Today’s price vs future invested capital
Peer Comparison
| Market Cap | EV/IC | P/E | ||||
|---|---|---|---|---|---|---|
| UK |
A
|
Akanda Corp
NASDAQ:AKAN
|
25.9m USD | 20.6 | -6.3 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
883B USD | 9.2 | 42.8 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
553.5B USD | 3.5 | 26.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 2.9 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.3B GBP | 3.8 | 28.3 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
270.2B USD | 2.6 | 14.8 | |
| CH |
|
Novartis AG
SIX:NOVN
|
216.3B CHF | 2.9 | 20.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 56 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 2.6 | 11.8 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.8B USD | 1.1 | 19.5 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122B USD | 2 | 17.3 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0 |
| Median | 0 |
| 70th Percentile | 0 |
| Max | 141.2 |
Other Multiples
Akanda Corp
Glance View
Akanda Corp. engages in cultivating cannabis. The firm is engaged in the cultivation, manufacturing, and distribution of cannabis. The firm cultivate and process natural cannabis at its facilities in the Kingdom of Lesotho, Africa and intend to supply medicinal-grade cannabis biomass, cannabis flower and cannabis concentrates to wholesalers in international markets. The firm also import and sell medical cannabis-based products to the domestic market in the United Kingdom. The Company’s subsidiaries include Bophelo Bio Science and Wellness (Pty) Limited, Canmart Limited, Bophelo Holdings Limited, and Cannahealth Limited. Bophelo Bio Science and Wellness (Pty) Limited is focused on the cultivation of cannabis, the production of medical cannabis products including dried flower, oils, and other concentrates. Canmart Limited is engaged in the production and sale of cannabis-based products for medicinal use.
